CABA
NASDAQ · Biotechnology
Cabaletta Bio Inc
$3.01
+0.10 (+3.44%)
Open$2.96
Previous Close$2.91
Day High$3.01
Day Low$2.93
52W High$4.23
52W Low$1.35
Volume—
Avg Volume3.44M
Market Cap442.69M
P/E Ratio—
EPS$-1.96
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,221.9% upside
Current
$3.01
$3.01
Target
$39.79
$39.79
$29.42
$39.79 avg
$58.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 65.93M | 59.67M | 56.91M |
| Net Income | 10.90M | 11.06M | 10.11M |
| Profit Margin | 16.5% | 18.5% | 17.8% |
| EBITDA | 19.62M | 16.47M | 16.10M |
| Free Cash Flow | 6.94M | 6.70M | 7.67M |
| Rev Growth | +19.8% | +7.9% | +20.9% |
| Debt/Equity | 0.22 | 0.21 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |